Is age-related decline in lean mass and physical function accelerated by obstructive lung disease or smoking?

Bram van den Borst,1,2 Annemarie Koster,2 Bingbing Yu,2 Harry R Gosker,1 Bernd Meibohm,3 Douglas C Bauer,4 Stephen B Kritchevsky,5 Yongmei Liu,6 Anne B Newman,7 Tamara B Harris,2 Annemie M W J Schols,1 For the Health ABC Study

ABSTRACT

Background and aims Cross-sectional studies suggest that obstructive lung disease (OLD) and smoking affect lean mass and mobility. A study was undertaken to investigate whether OLD and smoking accelerate the ageing-related decline in lean mass and physical functioning.

Methods 260 patients with OLD (mean±SD forced expiratory volume in 1 s (FEV1) 63±18% predicted), 157 smoking controls (FEV1 95±16% predicted), 866 former-smoking controls (FEV1 100±16% predicted) and 891 never-smoking controls (FEV1 104±17% predicted) participating in the Health, Aging and Body Composition (ABC) Study were studied. At baseline the mean age was 74±3 years and participants reported no functional limitations. Baseline and 7-year longitudinal data of body composition (by dual-energy x-ray absorptiometry), muscle strength (by hand and leg dynamometry) and Short Physical Performance Battery (SPPB) were investigated.

Results Compared with never-smoking controls, patients with OLD and smoking controls had a significantly lower weight, fat mass, lean mass and bone mineral content (BMC) at baseline (p<0.05). While the loss of weight, fat mass, lean mass and strength was comparable between patients with OLD and never-smoking controls, the SPPB declined 0.12 points/year faster in men with OLD (p=0.01) and BMC declined 4 g/year faster in women with OLD (p=0.02). In smoking controls only lean mass declined 0.1 kg/year faster in women (p=0.03) and BMC 8 g/year faster in men (p=0.02) compared with never-smoking controls.

Conclusions Initially well-functioning older adults with mild-to-moderate OLD and smokers without OLD have a comparable compromised baseline profile of body composition and physical functioning, while 7-year longitudinal trajectories are to a large extent comparable to those observed in never-smokers without OLD. This suggests a common insult earlier in life related to smoking.

Key messages

What is the key question?

► Is age-related decline in lean mass and physical function accelerated by Obstructive Lung Disease (OLD) or smoking?

What is the bottom line?

► Older adults with mild-to-moderate OLD and smokers without OLD have a comparable compromised baseline profile of body composition and physical functioning, while seven-year longitudinal trajectories are to a large extent comparable to those observed in never-smokers without OLD.

► This suggests a common insult earlier in life related to smoking.

Why read on?

► This is the first study analyzing the seven-year longitudinal pattern of body composition changes and the decline in physical functioning simultaneously in older adults with Obstructive Lung Disease (OLD) and in smokers without OLD in comparison with ageing effects in a never-smoking control group without OLD.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) affects approximately 14% of older adults and is related to increased immobility, hospitalisations and resulting healthcare costs.1 It is characterised by irreversible airflow limitation and is associated with an abnormal inflammatory response of the lungs mainly to cigarette smoke.2 It has been increasingly recognised as a disease with marked extrapulmonary manifestations such as muscle wasting and weakness, osteoporosis and cardiovascular disease,3 in which systemic inflammation is thought to play an important role.4,5 It remains unclear, however, if these systemic manifestations are comorbid conditions related to a common noxious exposure or if these are systemic consequences of the disease itself.

To date, skeletal muscle weakness and wasting are the most studied and established extrapulmonary determinants of impaired mobility and increased mortality in COPD.6 Putative pathophysiological mechanisms of altered body composition and physical functioning in COPD have originated from cross-sectional studies7–10 and from longitudinal case studies without appropriate control groups.11–14 However, since changes in body composition and dysregulation of inflammation are also common with ageing,15,16 and since...
Chronic obstructive pulmonary disease

studied COPD populations often consist of older adults (60 + years), inclusion of matched non-COPD control groups is crucial to unravel the effect of airflow obstruction on the pattern and progression of changes in body composition and physical function as well as the potential modulating role of systemic inflammatory markers. To our knowledge, such studies are currently lacking. Cross-sectional studies in healthy smokers have suggested detrimental effects of smoking on skeletal muscle function. Increased systemic levels of proinflammatory markers were observed in healthy smokers but also in former smokers. Collectively, these data suggest that, in the absence of chronic airflow limitation, smoking may enhance skeletal muscle wasting and accelerate the decline in physical functioning, and that systemic inflammation could be a modulator.

We hypothesised that older adults with obstructive lung disease (OLD) and smokers with normal lung function have accelerated loss of lean mass and physical functioning compared with a population of never-smokers. Systemic inflammatory markers could contribute to the association with body composition and physical functioning. We therefore examined 7-year longitudinal changes in body composition and physical functioning in older persons with OLD and in a non-OLD population stratified by smoking status.

METHODS
Study population
This study was performed in persons participating in the Health, Aging and Body Composition (Health ABC) study. This is a longitudinal study of 3075 well-functioning black and white men and women aged 70–79 years residing in and near Pittsburgh, Pennsylvania and Memphis, Tennessee. Baseline data were obtained in 1997/8 through in-person interview and clinic-based examination. Inclusion criteria were no reported difficulty in walking a quarter of a mile, climbing 10 steps without resting or performing mobility-related activities of daily living. Exclusion criteria were any life-threatening condition, participation in any research study involving medications or modification of eating or exercise habits, plans to move from the geographical area within 3 years and difficulty in communicating with the study personnel or cognitive impairment. The Health ABC study protocol was approved by the Institutional Review Boards of the clinical sites. Written informed consent was obtained for all participants. The current study presents an analysis of the Health ABC dataset using 7-year follow-up data from participants who met the criteria for OLD (n=260) and control participants with normal lung function (n=1914). Participants with missing body composition measures at baseline and those with no measures of systemic inflammatory markers were excluded (figure 1).

Measures
Lung function, smoking status and smoking history
Lung function was assessed according to international standards as previously reported. OLD was defined at baseline as restricted (ie, less than the lower limit of normal (LLN)) forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) as determined by age, sex and race-normalised values. Cigarette smoking status (smoker, former-smoker, never-smoker) was recorded based on self-report. At baseline, smokers, former-smokers and never-smokers without OLD (ie, FEV1/FVC ≥LLN) were designated as smoking controls, formerly-smoking controls and never-smoking controls, respectively. Participants with restrictive lung disease (FEV1/FVC <LLN but FVC ≥LLN) were excluded. At baseline the number of pack-years smoked (1 pack-year = 20 cigarettes/day for 1 year) was obtained based on self-report.

Lung function was repeated in years 5 and 8. Participants with valid lung function measures both at baseline and in years 5 and/or 8 were included in the analysis of lung function decline. Consequently, lung function decline could be analysed in 1658 participants over a mean (SD) period of 6.2 (1.3) years, including 2.6 (0.5) valid measurements per participant.

Body composition
Height was measured using a wall-mounted stadiometer. Body weight was assessed to the nearest 0.1 kg using a standard balance beam scale and body mass index (BMI) was calculated as weight/height² (kg/m²). Weight was measured in years 1–6 and 8. Whole body dual energy x-ray absorptiometry (DXA, Hologic 4500A software Version 8.21, Waltham, Massachusetts, USA) was applied to retrieve whole body fat mass, lean mass, leg lean mass (left and right leg were summed) and bone mineral content (BMC). DXA measurements were performed in years 1–6 and 8.

Muscle function and mobility
In years 1, 2, 4, 6 and 8, maximal isokinetic strength of the quadriceps muscle was assessed by a Kin-Com 125 AP Dynamometer (Chattanooga, Tennessee, USA) at 60°/s. The right leg was tested unless there was a contraindication. The maximum torque was taken from three reproducible and acceptable trials. Participants with a systolic blood pressure ≥200 mm Hg or a diastolic blood pressure ≥110 mm Hg or who reported a history of cerebral aneurysm, cerebral bleeding, bilateral total knee replacement or severe bilateral knee pain were excluded from testing (12.7% of the original cohort). As a consequence, baseline measures for quadriceps strength were available for 228 participants with OLD and 1750 controls. Hand grip strength was measured using a Jamar Hydraulic Hand Dynamometer at baseline and in years 2, 4, 6 and 8. The maximum values of the right and left hands were summed from two trials. In years 1, 4 and 6, lower extremity function was assessed using the Short Physical Performance Battery (SPPB). The battery consists of a test of gait speed, standing balance and time to rise from
Inability to complete test, 4".

a chair five times. Each item was scored using a 5-point scale (0 = inability to complete test, 4 = highest level of performance) leading to a combined 0–12 point summary scale.

Inflammatory markers
At baseline, measures of the cytokines interleukin 6 (IL-6), tumour necrosis factor α (TNF-α) and C reactive protein (CRP)

### Table 1: Baseline characteristics of women in the Health ABC Study according to obstructive lung disease (OLD) status and smoking status

<table>
<thead>
<tr>
<th></th>
<th>OLD (n = 150)</th>
<th>Smoking controls (n = 74)</th>
<th>Formerly-smoking controls (n = 534)</th>
<th>Never-smoking controls (n = 301)</th>
<th>Overall p value</th>
<th>Significant post hoc comparisons*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>73.4 (2.9)</td>
<td>73.0 (2.5)</td>
<td>73.7 (2.9)</td>
<td>74.0 (2.8)</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>Race, % white</td>
<td>52</td>
<td>35</td>
<td>70</td>
<td>65</td>
<td>&lt;0.001</td>
<td>AC, BC, BD</td>
</tr>
<tr>
<td>Site, % Memphis</td>
<td>60</td>
<td>50</td>
<td>47</td>
<td>51</td>
<td>0.013</td>
<td>AC, AD</td>
</tr>
<tr>
<td>Physical activity, kcal/kg/week†</td>
<td>68 (37–105)</td>
<td>59 (35–125)</td>
<td>67 (40–114)</td>
<td>72 (39–114)</td>
<td>0.68</td>
<td></td>
</tr>
<tr>
<td><strong>Comorbidity, steroid use, calcium and vitamin D supplementation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression, %</td>
<td>7</td>
<td>1</td>
<td>8</td>
<td>5</td>
<td>0.22</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular disease, %</td>
<td>25</td>
<td>24</td>
<td>30</td>
<td>23</td>
<td>0.10</td>
<td></td>
</tr>
<tr>
<td>Diabetes, %</td>
<td>13</td>
<td>15</td>
<td>16</td>
<td>15</td>
<td>0.91</td>
<td></td>
</tr>
<tr>
<td>Oral steroid use, %</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>0.49</td>
<td></td>
</tr>
<tr>
<td>Calcium supplementation, %</td>
<td>5</td>
<td>7</td>
<td>7</td>
<td>3</td>
<td>0.35</td>
<td></td>
</tr>
<tr>
<td>Vitamin D supplementation, %</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>4</td>
<td>0.63</td>
<td></td>
</tr>
<tr>
<td><strong>Lung function and smoking</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1, l</td>
<td>1.24 (0.38)</td>
<td>1.66 (0.53)</td>
<td>1.98 (0.66)</td>
<td>2.18 (0.78)</td>
<td>0.001</td>
<td>AB, AC, AD, BC, BD</td>
</tr>
<tr>
<td>CRP, g/ml</td>
<td>2.09 (1.07–3.72)</td>
<td>2.00 (1.17–3.95)</td>
<td>2.18 (1.27–3.83)</td>
<td>1.63 (0.95–3.07)</td>
<td>&lt;0.001</td>
<td>CD</td>
</tr>
<tr>
<td>TNF-α, pg/ml</td>
<td>2.92 (2.17–3.75)</td>
<td>3.06 (2.19–3.95)</td>
<td>3.02 (2.37–3.86)</td>
<td>3.10 (2.30–3.97)</td>
<td>0.63</td>
<td></td>
</tr>
<tr>
<td><strong>Systemic inflammatory markers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-6, pg/ml†</td>
<td>2.23 (1.59–3.58)</td>
<td>2.46 (1.62–3.91)</td>
<td>1.74 (1.19–2.70)</td>
<td>1.68 (1.18–2.32)</td>
<td>&lt;0.001</td>
<td>AC, AD</td>
</tr>
<tr>
<td>CRP, pg/ml†</td>
<td>2.00 (1.21–3.51)</td>
<td>1.54 (0.92–3.30)</td>
<td>1.34 (0.88–2.38)</td>
<td>1.30 (0.89–2.22)</td>
<td>&lt;0.001</td>
<td>AC, AD</td>
</tr>
<tr>
<td>TNF-α, pg/ml†</td>
<td>3.13 (2.41–4.32)</td>
<td>3.18 (2.34–4.47)</td>
<td>3.34 (2.59–4.26)</td>
<td>3.05 (2.43–4.00)</td>
<td>0.23</td>
<td></td>
</tr>
</tbody>
</table>

Data are mean (SD) unless specified otherwise.
*Corrected for multiple testing.
†Median (IQR).
‡From reference equations.²¹

### Table 2: Baseline characteristics of men in the Health ABC Study according to obstructive lung disease (OLD) status and smoking status

<table>
<thead>
<tr>
<th></th>
<th>OLD (n = 110)</th>
<th>Smoking controls (n = 83)</th>
<th>Formerly-smoking controls (n = 332)</th>
<th>Never-smoking controls (n = 590)</th>
<th>Overall p value</th>
<th>Significant post hoc comparisons*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>72.8 (2.8)</td>
<td>73.7 (3.0)</td>
<td>73.3 (2.8)</td>
<td>73.5 (2.9)</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>Race, % white</td>
<td>62</td>
<td>37</td>
<td>56</td>
<td>59</td>
<td>0.001</td>
<td>AB, BC, BD</td>
</tr>
<tr>
<td>Site, % Memphis</td>
<td>42</td>
<td>43</td>
<td>46</td>
<td>51</td>
<td>0.11</td>
<td></td>
</tr>
<tr>
<td>Physical activity, kcal/kg/week†</td>
<td>65 (36–91)</td>
<td>66 (36–107)</td>
<td>65 (40–97)</td>
<td>74 (45–113)</td>
<td>0.006</td>
<td>CD</td>
</tr>
<tr>
<td><strong>Comorbidity, steroid use, calcium and vitamin D supplementation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression, %</td>
<td>12</td>
<td>16</td>
<td>11</td>
<td>11</td>
<td>0.70</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular disease, %</td>
<td>18</td>
<td>27</td>
<td>22</td>
<td>17</td>
<td>0.42</td>
<td></td>
</tr>
<tr>
<td>Diabetes, %</td>
<td>10</td>
<td>15</td>
<td>11</td>
<td>13</td>
<td>0.63</td>
<td></td>
</tr>
<tr>
<td>Oral steroid use, %</td>
<td>9</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>0.001</td>
<td>AD</td>
</tr>
<tr>
<td>Calcium supplementation, %</td>
<td>27</td>
<td>24</td>
<td>29</td>
<td>32</td>
<td>0.35</td>
<td></td>
</tr>
<tr>
<td>Vitamin D supplementation, %</td>
<td>9</td>
<td>7</td>
<td>13</td>
<td>15</td>
<td>0.10</td>
<td></td>
</tr>
<tr>
<td><strong>Lung function and smoking</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1, l</td>
<td>1.68 (0.50)</td>
<td>2.47 (0.41)</td>
<td>2.77 (0.50)</td>
<td>2.78 (0.49)</td>
<td>&lt;0.001</td>
<td>AC, AD, BC, BD</td>
</tr>
<tr>
<td>CRP, pg/ml†</td>
<td>1.54 (0.92–3.30)</td>
<td>1.34 (0.88–2.39)</td>
<td>1.30 (0.89–2.22)</td>
<td>1.30 (0.89–2.22)</td>
<td>&lt;0.001</td>
<td>AC, AD, BD, CD</td>
</tr>
<tr>
<td>TNF-α, pg/ml†</td>
<td>3.13 (2.41–4.32)</td>
<td>3.18 (2.34–4.47)</td>
<td>3.34 (2.59–4.26)</td>
<td>3.05 (2.43–4.00)</td>
<td>0.23</td>
<td></td>
</tr>
<tr>
<td><strong>Systemic inflammatory markers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-6, pg/ml†</td>
<td>2.23 (1.59–3.58)</td>
<td>2.46 (1.62–3.91)</td>
<td>1.74 (1.19–2.70)</td>
<td>1.68 (1.18–2.32)</td>
<td>&lt;0.001</td>
<td>AC, AD, BD</td>
</tr>
<tr>
<td>CRP, pg/ml†</td>
<td>2.00 (1.21–3.51)</td>
<td>1.54 (0.92–3.30)</td>
<td>1.34 (0.88–2.39)</td>
<td>1.30 (0.89–2.22)</td>
<td>&lt;0.001</td>
<td>AC, AD, BD, CD</td>
</tr>
<tr>
<td>TNF-α, pg/ml†</td>
<td>3.13 (2.41–4.32)</td>
<td>3.18 (2.34–4.47)</td>
<td>3.34 (2.59–4.26)</td>
<td>3.05 (2.43–4.00)</td>
<td>0.23</td>
<td></td>
</tr>
</tbody>
</table>

Data are mean (SD) unless specified otherwise.
*Corrected for multiple testing.
†Median (IQR).
‡From reference equations.²¹

CRP, C reactive protein; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IL-6, interleukin 6; SPPB, short physical performance battery; TNF-α, tumour necrosis factor α.
were obtained from frozen stored plasma or serum (see Koster et al.\textsuperscript{25} for further details).

Covariates
At baseline, clinic site, age, race (black/white), oral steroid use, calcium supplementation and vitamin D supplementation were based on self-report. Prevalent health conditions (diabetes, cardiovascular disease and depression) were assessed based on self-report and medication inventory. Physical activity in the preceding 7 days was assessed at baseline by questionnaire.\textsuperscript{26,27}

Statistical analyses
Differences in descriptive characteristics at baseline between participants with OLD, smoking controls, formerly-smoking controls and never-smoking controls were tested using ANOVA for continuous variables, \(\chi^2\) for categorical variables and the Kruskal–Wallis test for continuous variables with skewed distributions. Post hoc comparisons were performed applying Bonferroni correction for multiple testing. Change in lung function could be calculated from a maximum of three time points only, hence per participant simple linear regression was applied to examine the yearly change (slope) in lung function. Subsequently, the mean slopes were tested between the study groups using ANOVA. The longitudinal data on body composition and physical functioning were analysed using multilevel regression models, allowing for the intercepts and slopes to vary between the four groups. This type of analysis takes into account the intraindividual correlation between repeated measurements and allows the inclusion of participants with incomplete data at follow-up. Therefore, no imputation of missing data was applied. The primary model included group
(OLD, smoking controls, formerly-smoking controls, never-smoking controls), age, race, clinic site, examination year (time), oral steroid use (yes/no), calcium supplementation (yes/no), vitamin D supplementation (yes/no), cardiovascular disease (yes/no), diabetes (yes/no), depression (yes/no), physical activity and an interaction term with time for all of these variables. The reported slopes are the coefficients of the interaction term group*time in which the never-smoking controls served as the reference group. In the second model, further adjustment was made for IL-6, TNF-α and CRP and their interactions with time. There were no significant interaction effects between race and clinic site with the group variable on changes in body composition or physical functioning (p > 0.05). Sample size considerations precluded examination of the effect of smoking status within the OLD group. The current analyses were performed for men and women separately because the gender distribution across the study groups was significantly different (p < 0.001), which was most pronounced in the formerly-smoking controls and never-smoking controls.

A small proportion of participants did not have measurements of body composition and physical functioning due to missing clinic visits while being alive. To examine the sensitivity of the results from the multilevel regression analyses to these missing observations, we used a joint model for the primary outcomes and missing probabilities. Statistical analyses were performed using PASW Statistics 17.0 (SPSS Inc). A p value <0.05 was considered statistically significant.

RESULTS

Baseline characteristics for men and women are presented in tables 1 and 2, respectively. The degree of airflow limitation in persons with OLD was mild (FEV1 >70% predicted), moderate (FEV1 50–70% predicted) and severe (FEV1 <50% predicted) in 32%, 38% and 30% of cases in men and in 36%, 41% and 23% of cases in women, respectively. The proportion of smokers, former-smokers and never-smokers in the OLD group was 63%, 28% and 9% in men and 46%, 27% and 27% in women, respectively. Compared with never-smoking controls, the decline in FEV1 was lower in men with OLD (−38±6 vs −57±3 ml/year, p=0.038) but not in women with OLD (−33±5 vs −40±2 ml/year, p=0.446) (see table 1 in online supplement). The formerly-smoking controls had abstained from smoking for 25 (14) years. The prevalence of comorbid conditions was not different across the groups (p>0.05). Participants with OLD and smoking controls had comparable levels of physical activity to never-smoking controls (p>0.05). In men, those with OLD had increased CRP and IL-6 levels, and smoking controls had higher IL-6 levels than never-smoking controls (p>0.05). In women, smoking controls had higher IL-6 levels than never-smoking controls (p<0.05).
Figure 3  Longitudinal course of body composition and physical functioning according to obstructive lung disease and smoking status in men. Lines represent the mean predicted values adjusted for time, age, site, race, diabetes, cardiovascular disease, depression, physical activity, oral steroid use, calcium supplementation, vitamin D supplementation, time\(^3\) age \(\times\) time, race \(\times\) time, site \(\times\) time, diabetes \(\times\) time, cardiovascular disease \(\times\) time, depression \(\times\) time and physical activity \(\times\) time, oral steroid use \(\times\) time, calcium supplementation \(\times\) time and vitamin D supplementation \(\times\) time. *Intercept significantly different from never-smoking controls (p<0.05). †Slope significantly different from never-smoking controls (p<0.05). OLD, obstructive lung disease; SPPB, Short Physical Performance Battery.
Figure 4  Longitudinal course of body composition and physical functioning according to obstructive lung disease and smoking status in women*. *Lines represent the mean predicted values adjusted for time, age, site, race, diabetes, cardiovascular disease, depression, physical activity, oral steroid use, calcium supplementation, vitamin D supplementation, time$^2$ age $\times$ time, race $\times$ time, site $\times$ time, diabetes $\times$ time, cardiovascular disease $\times$ time, depression $\times$ time and physical activity $\times$ time, oral steroid use $\times$ time, calcium supplementation $\times$ time and vitamin D supplementation $\times$ time. † Intercept significantly different from never-smoking controls (p < 0.05). ‡ Slope significantly different from never-smoking controls (p < 0.05). OLD, obstructive lung disease; SPPB, Short Physical Performance Battery.
In both sexes, persons with OLD and smoking controls showed striking similarities with regard to lower measures of body composition and physical functioning compared with never-smoking controls (figure 2). In general, the adjusted intercepts from the multilevel models (figures 3 and 4 and corresponding tables 2 and 3 in the online supplement) showed similar findings to the baseline comparisons in figure 2. While at baseline large differences were observed in body composition and physical functioning, the rates of longitudinal change of weight, fat mass, lean mass and strength were comparable between persons with OLD and never-smoking controls (all \( p > 0.05 \)), except for the change in SPPB in men with OLD (\( p = 0.01 \)) and BMC in women with OLD (\( p = 0.02 \)). In smoking controls only lean mass declined faster in women (\( p = 0.05 \)) and BMC faster in men (\( p = 0.02 \)) than in never-smoking controls, while the declines in weight and fat mass were comparable (\( p > 0.05 \)).

Further adjustment for baseline systemic cytokines resulted in a modest attenuation of several outcome measures (see tables 2 and 3 in online supplement). In particular, the lower baseline and faster decline of BMC in smoking control men (and women to a lesser extent) was explained by the cytokines for 12% and 26%, respectively. The lower quadriceps strength in men and women with OLD was explained by the cytokines for 12% and 18%, respectively.

In additional analyses, pack-years were added to model 1 but did not result in any major differences. Compared with never-smoking controls, formerly-smoking controls, smoking controls and participants with OLD had slightly higher probabilities of being missing during the 7-year follow-up period. However, the trajectories of the outcomes essentially remained the same when we adjusted for ‘missingsness’ (data not shown). The percentage of participants alive at the year 8 visit was 62%, 66%, 77% and 85% for persons with OLD, smoking controls, formerly-smoking controls and never-smoking controls, respectively.

### DISCUSSION

In this study we have shown striking similarities in body composition and physical functioning between older adult men and women with mild-to-moderate OLD and smokers with normal lung function. These were characterised by a markedly lower body weight, lean mass, fat mass, BMC and quadriceps strength compared with never-smoking controls. Interestingly, because longitudinal trajectories in the eighth decade of life were, to a large extent, comparable to those of their never-smoking controls, the large baseline differences persisted over a period of 7 years of follow-up. This suggests that a common insult related to smoking induced a divergent pattern earlier in life which may not uniformly persist into old age.

The unique design of the Health ABC Study enabled us to investigate for the first time the longitudinal pattern and progression of body composition changes and the decline in physical functioning simultaneously in persons with OLD and smokers without OLD in comparison with ageing effects in a never-smoking control group without OLD. Furthermore, by design of the Health ABC Study, none of the participants had functional limitations at baseline and, probably as a result of this selection, physical activity and the prevalence of comorbidity were comparable between the study groups. The Health ABC Study was therefore particularly of interest to examine the effects of smoking and OLD on body composition and physical functioning with ageing. Our results may, however, not be generalised to all older adults nor to patients with clinical COPD since study participants were aged 70–79 years and were well-functioning at baseline, and the OLD group was defined by lung function rather than a clinical COPD diagnosis. It therefore cannot be ruled out that our data might underestimate ‘real’ changes. Another strength of our study is that we carried out a sensitivity analysis to estimate the potential effect of missing observations on the observed trajectories. This effect was estimated to be small; however, this does not rule out the possibility that survival bias may have obscured our results. While we were unable to examine the effect of smoking status in the participants with OLD owing to sample size considerations, the results between the groups remained similar after further adjustment for pack-years, suggesting that the observed differences are independent of the quantity of smoking.

We found that the decline in FEV₁ was lower in men with OLD than in their never-smoking controls. Because these data were generated from a relatively low number of follow-up lung function measures, we are careful in its interpretation, but it does suggest that longitudinal body composition and physical functioning trajectories in persons with OLD in our study are not related to a faster decline in FEV₁.

In men with OLD but not in women, we found an accelerated decline in SPPB. This gender difference may be explained by a greater relative difference in leg lean mass and quadriceps strength between persons with OLD and never-smoking controls in men than in women. This is in line with a previous report showing that the relation between a lower fat-free mass and physical disability was more pronounced in men with COPD. A lower SPPB has been strongly related to subsequent disability and mortality, and may thus be of clinical importance, particularly in men with OLD. Notably, despite a similar pattern of daily physical activity, quadriceps strength was much better able to discriminate between persons with OLD, smoking controls and never-smoking controls than hand grip strength. Women in the smoking control group had an accelerated decline in lean mass compared with never-smoking controls, which confirms previous cross-sectional data of a sarcopenic phenotype in older women who smoke.

Systemic inflammation has been considered a key player in the extrapulmonary manifestations of COPD, and has been linked to muscle atrophy and bone demineralisation. In the present study we indeed confirmed the presence of mildly elevated circulating cytokines, particularly in men with OLD but also in smoking controls. After further adjustment for systemic inflammatory markers, we found little attenuation for the majority of outcome measures but systemic inflammatory markers did explain 11–26% of the observed baseline differences in BMC and 25% of the accelerated decline in men in the smoking control group.

The observation that smoking cessation is associated with weight gain is well known. While this effect is mainly considered a relatively short-term effect (months), former smokers in our study—who abstained from smoking for \( \sim 25 \) years—still showed a trend towards higher baseline weight which was mainly due to higher fat mass. Apart from fat mass, body composition and physical functioning in former smokers were comparable to that of never-smokers, suggesting a high recovery potential from smoking-induced losses. As higher body weight and lean mass have been associated with better survival in COPD, it needs to be determined whether this recovery potential is as functional in the state of COPD. We found higher CRP in women who formerly smoked and borderline significantly higher TNF-\( \alpha \) in men who formerly smoked, which may be related to metabolic effects associated with fat abundance or altered fat distribution in obesity.

Although it was not part of our analyses, our data raise the possibility that low body and muscle mass may increase the risk.
of COPD development. In support of this, recent data from a large group of never-smokers from the Burden of Obstructive Lung Disease Study showed that the risk of COPD was significantly increased in those with a BMI <20 kg/m², especially in women. In the case of smoking-induced COPD, however, it remains to be investigated whether a compromised body composition related to smoking contributes to the risk of COPD development. Our observation that the smoking controls had comparable pack-years smoked to participants with OLD and a similarly compromised body composition but no airflow obstruction indicates that it is not solely low body weight that increases the risk of COPD development, but suggests that other factors such as genetic susceptibility to, for example, emphysema and associated wasting are important.

In conclusion, our study shows that smoking is not only an important risk factor in the aetiology of OLD but also adversely affects body composition and physical functioning. The individual contributions of impaired weight gain and accelerated weight loss and a potential role for cytokinemic stress associated with smoking remain to be studied in comparable future longitudinal studies in middle-aged persons.

**Funding** This study was supported by National Institute on Aging contracts N01-AG-6-2101, N01-AG-6-2103 and N01-AG-6-2106 and National Heart Lung and Blood Institute grant R01-HL-74104. This research was supported (in part) by the Intramural Research Program of the NIH, National Institute on Aging. This study was performed within the framework of the Dutch Top Institute Pharma project T1-201, The Netherlands.

**Correction notice** This article has been corrected since it was published Online First. Figures 3 and 4 had incorrect footnote symbols.

**Competing interests** None.

**Patient consent** Obtained.

**Ethics approval** The Health ABC Study protocol was approved by the Institutional Review Board of the centers in Pittsburgh, Pennsylvania and Memphis, Tennessee.

**Contributors** BvdB, AK, HRG, TBH and AMWJS designed the study. BvdB performed the analyses, wrote the first draft of the manuscript and takes responsibility for the integrity of the manuscript. BY supervised the statistical analyses. AK, HRG, TBH and AMWJS supervised the study. BM, DCB, SBR, YL and ABN reviewed the manuscript.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**REFERENCES**


Is age-related decline in lean mass and physical function accelerated by obstructive lung disease or smoking?

Bram van den Borst, Annemarie Koster, Binbing Yu, Harry R Gosker, Bernd Meibohm, Douglas C Bauer, Stephen B Kritchevsky, Yongmei Liu, Anne B Newman, Tamara B Harris, Annemie M W J Schols and For the Health ABC Study

Thorax published online July 1, 2011

Updated information and services can be found at: http://thorax.bmj.com/content/early/2011/07/06/thoraxjnl-2011-200010

These include:

References

This article cites 37 articles, 10 of which you can access for free at: http://thorax.bmj.com/content/early/2011/07/06/thoraxjnl-2011-200010#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Health education (1223)
Smoking (1037)
Tobacco use (1039)
Radiology (diagnostics) (812)
Epidemiologic studies (1829)
Health policy (183)
Health service research (169)
Osteoporosis (36)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/